| Home | E-Submission | Sitemap | Contact Us |  
top_img
Cancer Research and Treatment > Volume 35(4); 2003 > Article
Editorial
Cancer Research and Treatment 2003;35(4): 279-280. doi: https://doi.org/10.4143/crt.2003.35.4.279
Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer: Past, Present, and Hope for the Future
Keunchil Park
Division of Hematology and Oncology, Department of Medicine,Samsung Medical Center, Sungkyunkwan University School ofMedicine, Seoul, Korea.
  Published online: August 31, 2003.
ABSTRACT
No abstract available.
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Share:      
METRICS
4
Crossref
0
Scopus
3,227
View
15
Download
Related articles
First-Line Alectinib vs. Brigatinib in Advanced Non–Small Cell Lung Cancer with ALK Rearrangement: Real-World Data  2024 January;56(1)
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea  2020 January;52(1)
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer  2018 July;50(3)
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer  2015 October;47(4)
Neoadjuvant Chemotherapy in Locally Advanced Non - Small Cell Lung Cancer  1995 ;27(4)
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI